MA44557A1 - Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer - Google Patents

Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer

Info

Publication number
MA44557A1
MA44557A1 MA44557A MA44557A MA44557A1 MA 44557 A1 MA44557 A1 MA 44557A1 MA 44557 A MA44557 A MA 44557A MA 44557 A MA44557 A MA 44557A MA 44557 A1 MA44557 A1 MA 44557A1
Authority
MA
Morocco
Prior art keywords
vaccine
buffer
low dose
administer
dose volume
Prior art date
Application number
MA44557A
Other languages
English (en)
Other versions
MA44557B1 (fr
Inventor
Krishna Mohan Vadrevu
Sai Devarajulu Prasad
Krishna Murthy Ella
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of MA44557A1 publication Critical patent/MA44557A1/fr
Publication of MA44557B1 publication Critical patent/MA44557B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer. Le vaccin est disponible sous la forme de doses d'un volume inférieur à 1 ml par dose destinées à être administrées par voie orale, et ne contient pas de tampon. Le vaccin ne nécessite pas d'administration, avant ou après l'administration par voie orale du vaccin au patient, d'anti-acide qui viserait à neutraliser l'acidité gastrique. Le vaccin montre une diminution de la ch
MA44557A 2016-06-16 2017-06-12 Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer MA44557B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641020675 2016-06-16
PCT/IN2017/050237 WO2017216808A1 (fr) 2016-06-16 2017-06-13 Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer

Publications (2)

Publication Number Publication Date
MA44557A1 true MA44557A1 (fr) 2020-01-31
MA44557B1 MA44557B1 (fr) 2021-11-30

Family

ID=60664101

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44557A MA44557B1 (fr) 2016-06-16 2017-06-12 Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer

Country Status (22)

Country Link
US (1) US11351245B2 (fr)
EP (1) EP3471768A4 (fr)
JP (1) JP7108549B2 (fr)
KR (3) KR20220063302A (fr)
CN (1) CN109562159B (fr)
AU (1) AU2017285408B2 (fr)
BR (1) BR112018076094A2 (fr)
CA (1) CA3027703A1 (fr)
CO (1) CO2019000078A2 (fr)
EA (1) EA201990027A1 (fr)
GB (1) GB2566244B (fr)
IL (1) IL263740B2 (fr)
JO (1) JOP20180124A1 (fr)
MA (1) MA44557B1 (fr)
MX (1) MX2018015469A (fr)
MY (1) MY198419A (fr)
PH (1) PH12018502650A1 (fr)
SG (2) SG10202012281TA (fr)
TN (1) TN2018000436A1 (fr)
UA (1) UA124430C2 (fr)
WO (1) WO2017216808A1 (fr)
ZA (1) ZA201900176B (fr)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
PT939648E (pt) 1996-09-26 2008-01-11 Merck & Co Inc Formulações de vacinas de rotavírus
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
CN1209837A (zh) * 1996-10-18 1999-03-03 财团法人阪大微生物病研会 用于轮状病毒感染的轮状病毒属抗原、疫苗和诊断试剂以及用于产生抗原的方法
CA2336875C (fr) * 1998-07-28 2014-01-07 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Vaccin antirotavirus polyvalent humain-bovin
DK1212084T3 (da) 1999-08-17 2006-07-10 Glaxosmithkline Biolog Sa Fremgangsmåde til adskillelse af rotavirus-varianter samt levende, svækket rotavirus-vaccine
JP2005038411A (ja) 2003-06-30 2005-02-10 Sony Corp 機器認証情報組込システム、端末機器、機器認証情報処理方法、機器認証情報処理プログラム、提供サーバ、機器認証情報提供方法、機器認証情報提供プログラム、及び記憶媒体
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0516944D0 (en) * 2005-08-17 2005-09-28 Glaxosmithkline Biolog Sa Vaccine
US9642907B2 (en) * 2006-05-12 2017-05-09 Bharat Biotech International Limited Stabilized liquid rotavirus vaccine composition
CN101638638A (zh) * 2008-07-29 2010-02-03 辽宁依生生物制药有限公司 人猪重配轮状病毒
CN102470170B (zh) * 2009-07-13 2015-03-18 巴拉特生物技术国际有限公司 用作轮状病毒疫苗的组合物及其方法
BR112013027457A2 (pt) * 2011-04-28 2019-09-24 Int Medica Foundation preparação de vacina, e, métodos de fabricar uma preparação de vacina, e de vacinar um mamífero
BR112014026407B1 (pt) 2012-04-23 2020-12-22 Bharat Biotech International Limited formulação de vacina líquida

Also Published As

Publication number Publication date
JOP20180124A1 (ar) 2019-01-30
EP3471768A1 (fr) 2019-04-24
US11351245B2 (en) 2022-06-07
AU2017285408B2 (en) 2024-05-02
KR20220063302A (ko) 2022-05-17
CO2019000078A2 (es) 2019-01-18
ZA201900176B (en) 2019-09-25
UA124430C2 (uk) 2021-09-15
MA44557B1 (fr) 2021-11-30
BR112018076094A2 (pt) 2019-03-26
TN2018000436A1 (en) 2020-06-15
CN109562159B (zh) 2022-10-28
GB201900562D0 (en) 2019-03-06
JP2019518056A (ja) 2019-06-27
EP3471768A4 (fr) 2020-03-04
KR20190020046A (ko) 2019-02-27
MX2018015469A (es) 2019-04-24
AU2017285408A1 (en) 2019-01-31
IL263740B1 (en) 2023-09-01
WO2017216808A1 (fr) 2017-12-21
SG10202012281TA (en) 2021-01-28
US20190142932A1 (en) 2019-05-16
SG11201811188TA (en) 2019-01-30
EA201990027A1 (ru) 2019-07-31
GB2566244B (en) 2021-10-13
MY198419A (en) 2023-08-29
JP7108549B2 (ja) 2022-07-28
GB2566244A (en) 2019-03-06
IL263740A (en) 2019-01-31
CA3027703A1 (fr) 2017-12-21
PH12018502650A1 (en) 2019-10-07
CN109562159A (zh) 2019-04-02
IL263740B2 (en) 2024-01-01
KR20230125863A (ko) 2023-08-29

Similar Documents

Publication Publication Date Title
EA201790568A1 (ru) Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
CL2019003091A1 (es) Terapia de combinación.
EA202090573A1 (ru) Составы нирапариба
CA3030422C (fr) Excipients stabilisants pour formulations de proteines therapeutiques
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
RU2017134443A (ru) Способ лечения с применением традипитанта
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
EA201792591A1 (ru) Фармацевтические препараты
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
IT201800001301A1 (it) Formulazioni in gel per la somministrazione orale di farmaci, in particolare nei pazienti disfagici
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
ECSP17064188A (es) Formulación estable para administración parenteral de tapentadol
PH12019500516A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
MX2020000009A (es) Nuevas formulaciones en capsulas de gelatina blandas de secnidazol y sus usos.
MA44557A1 (fr) Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
FI3137094T3 (fi) Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
MX2019006548A (es) Composicion para el tratamiento de la osteoartritis.
MX2021004138A (es) Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias.
CY1120282T1 (el) Φαρμακευτικη συνθεση κιτρικης σιλδεναφιλης με την μορφη ενος εναιωρηματος για εκ του στοματος χρηση
EA202090287A1 (ru) Составы пролонгированного действия